Abstract: A method of treating or preventing a neurodegenerative disorder or a peripheral autoimmune disorder is disclosed. The method comprises administering to a patient in need thereof a combination of (a) tauroursodeoxycholic acid (TUDCA) or ursodeoxycholic acid (UDCA), (b) coenzyme Q10 (CoQ10) as ubiquinone or ubiquinol, and (c) creatine. The combination is shown to have synergistic effects in reducing the inflammatory cytokines IL-6 and TNF-?. The combination also significantly increases NFH filament and tubulin filament areas suggesting improved neuronal growth. Unit dosage forms are disclosed. Dosages are disclosed.

Abstract: Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.

Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids, an effective amount of a compound (e.g., psilocybin/psilocin) for treating drug addiction (e.g. opioid addiction) and menthol where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid. The present disclosure also disclosure relates to compositions, including, hydrogel compositions useful as topical analgesics including cannabinoids and menthol as well as carboxymethyl cellulose, carrageenan and a cross-linking agent.

Abstract: The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

Abstract: The present invention refers generally to the field of nutrition, in particular performance nutrition. More specifically, it refers to a food product, its use as sports supplement and its use for increasing performance, energy, power, and/or strength during exercise; for improving recovery after exercise; and for reducing fatigue during exercise and/or after exercise.

Abstract: The present invention relates to the field of microbial growth, more specifically microbial overgrowth, even more specifically overgrowth of Enterobacteriaceae, specifically under conditions of apoptosis in the gut such as IBD, colitis, chemotherapy and food borne bacterial infections. The present invention provides inhibitors of a bacterial target, pyruvate formate lyase, which can be used to regulate the overgrowth of Enterobacteriacea.

Abstract: Provided herein are solid dosage forms comprising 2,3,4,5-tetrahydro-benzothiepin-1,1-dioxide derivatives, for example volixibat or a pharmaceutically acceptable salt thereof. Also provided herein are embodiments directed to methods of treating cholestatic liver disease, hyperlipidemia, arteriosclerosis, or Syndrome X, or lowering the serum cholesterol level in a subject in need thereof, wherein the methods comprise administering to the subject a therapeutically effective amount of the solid dosage form of the pharmaceutical composition comprising volixibat.

Abstract: A regenerative agent for bone tissue and lung tissue contains a macrolide antimicrobial agent as an active ingredient. The macrolide antimicrobial agent may be one or more selected from the group consisting of erythromycin, azithromycin, and clarithromycin. The regenerative agent for bone tissue and lung tissue may be locally administered to bone tissue or lung tissue. A pharmaceutical composition for regenerating bone tissue and lung tissue contains the regenerative agent for bone tissue and lung tissue, and a pharmaceutically acceptable carrier.

Abstract: The present invention conveys a fractionation method to isolate different bioactive Phytocannabinoids by solid phase extraction using HP-20 resins and one step method to synthesize C— and O-?-D-glycoside derivatives of Cannabinoid by using a ?-D-glucose donor (O-Glycosyl trichloroacetimidate donor) to obtain glycosidic derivatives. The novel C-glycosides of Cannabinoids displayed significant anti-proliferative properties against wide range of human cancer cell lines as compared to their respective parent molecules. Furthermore, the C— and O glycosides of Cannabinoids also showed anti-invasive and anti-migratory activities against metastatic cancer cells of breast and pancreatic origin. When applied in combination with DNA damaging agent (5-Fluorouracil) to colorectal cancer cells, the C— and O-glycosides of Cannabinoids potentiate DNA damaging property and thus augment apoptosis resulting in an increment in the efficacy of DNA damaging drugs.

Abstract: The present invention provides a new combinatorial drug or a new pharmaceutical composition comprising nitazoxanide, atovaquone and/or ribavirin, and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.

Abstract: Nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof in which a therapeutically effective amount of the nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof is administered to the subject.

Abstract: The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or/and an antioxidant.

Abstract: Aspects of the disclosure relate to molecular payloads that modulate the expression or activity of genes involved in muscle growth and maintenance (e.g., MSTN, INHBA, ACVR1B, MLCK1, ACVR1, FBXO32, TRIM63, MEF2D, KLF15, MED1, MED13, and/or PPP1R3A), and complexes comprising a muscle-targeting agent covalently linked to such molecular payloads. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell (e.g., a cardiac muscle cell, a smooth muscle cell, a skeletal muscle cell). In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Abstract: Provided are a siRNA for inhibiting the expression of hepatitis B virus gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is independently a modified nucleotide. The siRNA includes a sense strand and an antisense strand. The sense strand of the siRNA includes a nucleotide sequence 1 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 155, and the antisense strand of the siRNA includes a nucleotide sequence 2 having the same length and no more than three nucleotides different from the nucleotide sequence shown in SEQ ID NO: 156.

Abstract: The present disclosure provides a water-soluble dietary fiber (WSDF), use thereof in preparation of a medicament that promotes metabolism of ellagic acid (EA) into urolithin A, and a pharmaceutical composition, and belongs to the technical field of biological pharmaceuticals. The WSDF provided by the present disclosure includes at least two components selected from the group consisting of gellan gum, guar gum, carrageenan, fructooligosaccharide, xylooligosaccharide, malto-oligosaccharide, pectin, ?-glucan, polydextrose, sodium alginate, gum arabic, resistant dextrin, xanthan gum, tragacanth gum, and inulin. In the present disclosure, compounding the foregoing different combinations of the WSDF and EA to feed mice may significantly increase the average urolithin A content in mouse feces.

Abstract: The invention relates to a pharmaceutical composition, as well as a dosage comprising said pharmaceutical composition, and a medicament for use in the treatment of a mitochondrial activity related disease or disorder and/or of an adiponectin production related disease or disorder, and said pharmaceutical composition as a medicament. It has been found that the present composition contributes positively in the recovery, the treatment, and reducing negative effects of such cell-related diseases and disorders.

Abstract: Disclosed is a topical dermatological composition that generates nitric acid in situ for the treatment of dermatological conditions.

Abstract: A composition according to an embodiment includes a selenium-containing material and an antioxidant. The composition may inhibit degeneration of cartilage by a mechanism such as reducing oxidative stress in cells constituting the cartilage. Accordingly, it is possible to inhibit an occurrence of osteoarthritis, delay its progression, or enable treatment of osteoarthritis.

Abstract: A composition including a monovalent copper compound and Porphyridium sp. Polysaccharide (PS). Methods of making the composition are also disclosed.

Abstract: The present invention pertains to a composition for preventing and treating cancer through mitochondrial metabolism regulation, wherein the composition contains a nanographene structure. It has been confirmed that a specific inhibitory activity on the NIX-dependent pathway among the mitophagy mechanisms in cancer cells inhibits mitochondrial degradation, and thus damaged mitochondria accumulate in the cancer cells, and apoptosis of the cancer cells is induced as a result. Therefore, the composition according to the present invention exhibits excellent anticancer effects that can be applied to various diseases related to the accumulation of abnormal cells, without causing resistance or toxicity, and can thus be effectively used as a cancer prevention or treatment agent or an anticancer treatment adjuvant.

Abstract: Embodiments of the disclosure include methods and compositions related to targeting of antigen-expressing cells with particular engineered antigen receptors expressed by immune cells. In specific embodiments, immune cells specifically engineered to express particular antigen receptor constructs are cultured in the presence of kinase inhibitors and exhibit reduced fratricidal activity compared to immune cells cultured in the absence of kinase inhibitors. In some embodiments, the genetically engineered immune cells having reduced fratricidal activity are used to treat diseases in subjects, and the fratricidal activity of the genetically engineered immune cells is restored in vivo after substantial elimination of the diseased cells, resulting in elimination of the genetically engineered immune cells.

Abstract: An isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. Also disclosed is a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.

Abstract: Provided are methods and compositions for use in cancer immunotherapies. Exemplary compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In some embodiments, derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Abstract: This document relates to methods and materials related to isolated polypeptides, polypeptide preparations, and methods for using one or more isolated polypeptides to activate T cells. For example, polypeptides that can be used to activate T cells to generate antigen-specific T cells are provided. In some cases, T cells activated as described herein can be administered to a mammal having cancer (e.g., MM) or a precancerous condition (e.g., MGUS) to treat the mammal (e.g., to induce an immune response against the cancer or the precancerous condition).

Abstract: The invention relates to the field of cancer immunotherapy by employing CD4+ cell populations, CD8+ cell populations, or a combination thereof, comprising bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs for use in cancer treatment therapies.

Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.

Abstract: Compositions and methods for treating ovarian disorders or diseases conditions such as polyovarian insufficiency (POI) or polycystic ovary syndrome (PCOS) are provided. The methods include administering an exosome composition and a mesenchymal stem cell composition to a subject in need thereof.

Abstract: The present disclosure provides methods and compositions for genetically modifying hematopoietic stem and progenitor cells (HSPCs), in particular by correcting a JAK2V617F mutation in the HSPCs.

Abstract: Provided herein are methods, compositions of matter, and devices for treating neurological diseases and illnesses, including spinal cord injury.

Abstract: A device for preparing fat harvested from a first area of a patient's body for reinjection into a second area of the patient's body. The device includes: a structure having first and second branches to which first and second syringes are connected; and a connecting element which fits into the structure, connects the two branches, and has a membrane for filtering the fat. The connecting element is connected to a third syringe and assumes at least: an emulsification position forming with the first and second branches a first circulation circuit for the fat between the first syringe and the second syringe; and a transfer position forming with the first or second branches a second circulation circuit for the fat between the first or second syringe and the third syringe.

Abstract: Disclosed herein are methods for directing the differentiation of stem cells towards a specific cell type.

Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Abstract: The present disclosure provides use of a human umbilical cord mesenchymal stem cell-derived small extracellular vesicle (hucMSC-sEV) in preparation of a drug for treating type 2 diabetes mellitus (T2DM), and belongs to the technical field of biomedicine. In the present disclosure, experiments have verified that the hucMSC-SEV can effectively reduce blood glucose in a db/db mouse model, improve a morphological disorder of pancreatic islets, and increase a number of ? cells. Moreover, the hucMSC-sEV can also remodel pancreatic ? cells by reversing apoptosis and dedifferentiation of the ? cells. It is confirmed that the hucMSC-sEV is an effective pharmaceutical ingredient that improves pancreatic islet functions, and can effectively ameliorate T2DM, regulate glucose homeostasis, improve a pancreatic islet structure, and increase a quality of the pancreatic islet ? cells, thereby achieving therapeutic effects from a root cause of the disease.

Abstract: The present disclosure provides cells enriched with mitochondria to treat myelodysplastic syndrome (MDS). diseases and disorders. The disclosure provides pharmaceutical compositions of mitochondrially-enriched stem cells and/or progenitor cells. methods of treatment of myelodysplastic syndrome. and methods to alleviate symptoms of MDS and/or prevent the progression of MDS using mitochondrially-enriched stem cells and/or progenitor cells.

Abstract: This invention relates to a broad-spectrum antimicrobial marine biologic composition for bloodstream infections, derived from smeLAL and optional hemolymph of sustainable aquaculture horseshoe crabs. The formulation serves as an injectable treatment with broad-spectrum antimicrobial activity and an array of therapeutic mechanisms. In one embodiment, subject to clinical studies and characterization of cross-species immunogenicity, the composition may act as a breakthrough antimicrobial—or as a last-resort therapy for critically ill sepsis patients. In an alternative embodiment, the biologically derived antimicrobial agent represents a viable primary therapy with advantages over synthetic antibiotics, including a rapid therapeutic window. Given unmatched efficacy, an adjuvant smeLAL immunoglobulin therapy may be warranted to allow routine use if needed to address cross-species immunogenicity.

Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.

Abstract: The present invention concerns genetically modified Mycoplasma bacteria that express gene products having an anti-biofilm activity against a biofilm formed by multiple bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus. Further intended are pharmaceutical compositions comprising genetically modified Mycoplasma bacteria and their use as a medicament.

Abstract: Provided is a prophylactic and/or therapeutic agent for Porphyromonas gingivalis infection. A prophylactic and/or therapeutic agent for Porphyromonas gingivalis infection, comprising killed Enterococcus faecalis. A prophylactic and/or therapeutic agent for a disease attributable to Porphyromonas gingivalis, comprising killed Enterococcus faecalis. A medicine or food for prevention and/or treatment of Porphyromonas gingivalis infection, comprising killed Enterococcus faecalis. A medicine or food for prevention and/or treatment of a disease attributable to Porphyromonas gingivalis, comprising killed Enterococcus faecalis. A growth inhibitor for Porphyromonas gingivalis, comprising killed Enterococcus faecalis. An inhibitor for gingipain activity, comprising killed Enterococcus faecalis.

Abstract: The present disclosure provides use of an intestinal probiotic in preparation of a medicament that promotes metabolism of ellagic acid (EA) into urolithin A, a pharmaceutical composition and use thereof, and belongs to the technical field of biomedicine. In the present disclosure, probiotics capable of changing metabotypes of EA are selected from a plurality of probiotics. These probiotics alone or in combination can change an intestinal flora structure of a metabotype B and/or 0 population, thereby improving the efficiency of the metabolism of EA into urolithin A and increasing a yield of urolithin A. The present disclosure provides an intestinal probiotic for involving in and promoting the metabolism of EA into urolithin A, and provides a new idea for the treatment of diabetes, obesity, senescence, and diseases caused by central nervous system lesions and viral infection using urolithin A as an active pharmaceutical ingredient.

Abstract: The present invention relates to methods and compositions for treating cattle to modulate the abundance of Fusobacterium varium in the gastrointestinal tract with the intent to reduce liver abscess occurrence or severity, or to improve cattle growth or feed efficiency.

Abstract: The present invention relates to viral formulations for administration to a subject.

Abstract: The present invention relates to viral formulations for administration to a subject.

Abstract: The present disclosure generally relates to a microneedle patch composition capable of delivering therapeutically active ingredients to a perilesional site for treatment of a skin condition. The present disclosure also relates to a method of treating a skin condition comprising applying a dissolvable microneedle patch perilesionally wherein the dissolvable microneedle patch comprising a plurality of microneedles; a therapeutically active ingredient and a biodegradable polymer.

Abstract: Provided is a pharmaceutical composition for anti-obesity and preventing or treating muscle loss, which contains an extract of a plant in the genus Ulmus as an active ingredient.

Abstract: A composition for preventing, ameliorating or treating a respiratory disease includes fermented Centella asiatica extract as effective component. The composition is effective in, in bronchial epithelial cells as respiratory cells, reducing the production amount of the inflammatory chemokine RANTES, protecting damaged cells induced by LPS, and reducing the expression level of the inflammatory cytokine IL-6, and it can also reduce the neutrophil count and regulate the expression level of inflammatory cytokines or chemokines in an animal model of lung injury. Accordingly, it can be advantageously used for a functional health food for preventing or ameliorating a respiratory disease, or a pharmaceutical product for preventing or treating a respiratory disease.

Abstract: The present invention relates to a method of preparing fermented herbal eye drops, and the method includes an herbal medicine washing process of mixing an herbal medicine mixture, vinegar, and coarse salt in purified water, allowing it to stand, and then washing it; a heating process of inputting the herbal medicine mixture washed through the herbal medicine washing process into a decoction pot, mixing the herbal medicine mixture with purified water, and heating the herbal medicine mixture mixed with purified water; a cooling and fermentation process of cooling decoction prepared through the heating process and then fermenting the decoction; an eye drop raw material extraction process of distilling a fermented product prepared through the cooling and fermentation process to extract raw materials for eye drops; and an alkaline water mixing process of mixing alkaline water with the raw materials for eye drops prepared through the eye drop raw material extraction process.

Abstract: The present invention relates to a pharmaceutical composition for conditioning dampness-heat. The pharmaceutical composition consists of licorice root, forsythia shell, tree peony root bark, baical skullcap root, cassia twig, root of Chinese thorowax, Oroxylum indicum seed, mulberry leaf, prunella vulgaris, honeysuckle and perilla leaf. Herein, ratio of the licorice root to forsythia shell to tree peony root bark to baical skullcap root to cassia twig to root of Chinese thorowax to Oroxylum indicum seed to mulberry leaf to prunella vulgaris to honeysuckle and to perilla leaf is about 3:10:10:10:8:10:2:10:5:7:3.

Abstract: Extracts of the leaves, bark, and seeds/fruits of Castanea sativa Mill., syn. Castanea vesca Gaertn., and extracts of aerial parts of Cistus x incanus L., possess antibacterial activity against Helicobacter pylori and anti-inflammatory activity at the gastric level, and are therefore useful to relieve gastrointestinal inflammations, in particular those caused by Helicobacter pylori.

Abstract: The present invention generally relates to the use of a mulberry extract to improve sleep quality and/or subsequent behavioural outcomes. More particularly, the present disclosure relates to administration of a supplement comprising a mulberry extract, at a predetermined time before consumption of a meal and/or concurrently with consumption of a meal. Preferably the meal is a balanced evening meal.

Abstract: The subject matter of the invention is an aqueous solution for mucocutaneous administration, containing a plant matrix selected from plants or parts of plants of the Myrtaceae family in a solvent that is an aqueous solution with a pH of 7.5 or greater. The invention also covers a process for preparing such a solution. The solution according to the invention is used specifically in the prevention or treatment of infectious diseases.